NEW YORK, NY / ACCESSWIRE / August 29, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.
Omnicell, Inc. (NASDAQGS:OMCL)
Lawsuit on behalf of: investors who purchased October 25, 2018 - July 11, 2019
Lead Plaintiff Deadline : September 16, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/omnicell-inc-loss-form?prid=3256&wire=1
According to the filed complaint, during the class period, Omnicell, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Mallinckrodt Public Limited Company (NYSE:MNK)
Lawsuit on behalf of: investors who purchased February 28, 2018 - July 16, 2019
Lead Plaintiff Deadline : September 24, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mallinckrodt-public-limited-company-loss-form?prid=3256&wire=1
According to the filed complaint, during the class period, Mallinckrodt Public Limited Company made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Valaris plc (NYSE:VAL)
Lawsuit on behalf of: investors who purchased April 11, 2019 - July 31, 2019
Lead Plaintiff Deadline : October 21, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/valaris-plc-loss-form?prid=3256&wire=1
According to the filed complaint, during the class period, Valaris plc made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company’s second quarter 2019 results; (iii) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP